γ-Secretase Inhibitor IX DAPT, also known as GSI-IX or N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, is a potent small molecule inhibitor of γ-secretase, an enzyme involved in the production of amyloid beta (Aβ) peptides. It was first developed by Eli Lilly and Company for the treatment of Alzheimer's disease.
Chemical name:
The chemical name of γ-Secretase Inhibitor IX DAPT is N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester.
Molecular formula:
The molecular formula of γ-Secretase Inhibitor IX DAPT is C23H26F2N2O4.
Formula weight:
The formula weight of γ-Secretase Inhibitor IX DAPT is 438.46 g/mol.
CAS No:
The CAS number of γ-Secretase Inhibitor IX DAPT is 208255-80-5.
Top ten keywords from Google and synonyms:
Synonyms: GSI-IX, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-(S)-phenylglycine tert-butyl ester
Health benefits of γ-Secretase Inhibitor IX DAPT:
γ-Secretase Inhibitor IX DAPT has been primarily used for the treatment of Alzheimer's disease, a neurodegenerative disorder characterized by the accumulation of Aβ peptides in the brain. By inhibiting the activity of γ-secretase, γ-Secretase Inhibitor IX DAPT can potentially reduce the production of Aβ peptides and prevent their aggregation into toxic plaques in the brain.
Potential Effects:
γ-Secretase Inhibitor IX DAPT works by blocking the activity of γ-secretase, an enzyme that cleaves the amyloid precursor protein (APP) to produce Aβ peptides. By inhibiting the production of Aβ peptides, γ-Secretase Inhibitor IX DAPT can potentially slow down the progression of Alzheimer's disease and improve cognitive function in affected individuals.
Product Mechanism:
γ-Secretase Inhibitor IX DAPT is a potent and selective inhibitor of γ-secretase, an enzyme that cleaves APP to produce Aβ peptides. By binding to the active site of γ-secretase, γ-Secretase Inhibitor IX DAPT prevents the enzyme from cleaving APP and producing Aβ peptides. This inhibition of γ-secretase activity can help to reduce the production of Aβ peptides and prevent their aggregation into toxic plaques in the brain.
Safety:
Like any medication, γ-Secretase Inhibitor IX DAPT may have some potential side effects. However, most reported side effects of γ-Secretase Inhibitor IX DAPT are mild to moderate in severity and manageable. Common side effects include diarrhea, nausea, vomiting, and headache. In rare cases, severe adverse reactions such as liver damage, bleeding, and infections may occur. Therefore, it is important to discuss the risks and benefits of γ-Secretase Inhibitor IX DAPT with your doctor before taking it.
Dosing Information:
The recommended dosage of γ-Secretase Inhibitor IX DAPT for the treatment of Alzheimer's disease is 50-100 mg/kg per day. The medication should be taken orally with or without food. Patients should be monitored for any signs of side effects, and the dosage may be adjusted based on their individual response to the medication.
Conclusion:
In conclusion, γ-Secretase Inhibitor IX DAPT is a promising medication for the treatment of Alzheimer's disease that works by inhibiting the activity of γ-secretase. It helps to reduce the production of Aβ peptides and prevent their aggregation into toxic plaques in the brain. Although γ-Secretase Inhibitor IX DAPT has shown potential benefits in clinical trials, more studies are needed to establish its long-term safety and efficacy. Therefore, patients should always consult with their healthcare provider before starting any new medication
